A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Ibrutinib (Primary) ; Ixazomib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PrE0404
- 16 Jan 2024 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results assessing the safety and efficacy of Ixazomib and ibrutinib (ibr) in r/r MCL presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 31 Mar 2022 Planned End Date changed from 1 Nov 2024 to 1 Jul 2024.